#1
|
||||
|
||||
Íîâûå ïåðñïåêòèâû â ëå÷åíèè äèàáåòà 2-ãî òèïà
Â÷åðà â Ñàí-Äèåãî:
Öèòàòà:
|
#2
|
||||
|
||||
Îëüãà Þðüåâíà, ñïàñèáî áîëüøîå çà íîâóþ èíôîðìàöèþ!
Âûñêàæó ìíåíèå. Íàâåðíîå, ñåêðåòàãîãè ñ ìèíèìàëüíûì ðèñêîì ãèïîãëèêåìèé (ïðàâäà, ðèñê ãèïî ìåíüøå, ÷åì â ãðóïïå ïëàöåáî äàæå íàñòîðàæèâàåò) è íå óñòóïàþùèå ïî ýôôåêòèâíîñòè ïðîèçâîäíûì ñóëüôîíèëìî÷åâèíû äîëæíû ÿâèòüñÿ äëÿ ïîñëåäíèõ äîñòîéíîé àëüòåðíàòèâîé è äàæå ñìåñòèòü èõ ñ ðûíêà. Íî, êàê ìíå êàæåòñÿ, áóäåò íåñêîëüêî "íî": 1) ïðèä¸òñÿ ïðåîäîëåòü âñ¸ âîçðàñòàþùèå âûñî÷àéøèå òðåáîâàíèÿ ïî áåçîïàñíîñòè, ïðåäúÿâëÿåìûå ñåãîäíÿ ê ñàõàðîñíèæàþùèì ïðåïàðàòàì 2) äîëæíî ïðîéòè íåìàëî âðåìåíè äëÿ ïîëó÷åíèÿ äîêàçàòåëüñòâ ïî ïåðâè÷íûì êîíå÷íûì òî÷êàì 3) äëÿ çàâîåâàíèÿ øèðîêîãî ðûíêà GPR40 ïðèä¸òñÿ êàê ìèíèìóì çàî÷íî ñõëåñòíóòüñÿ ñ èíêðåòèíàìè, ïîáåäà íàä êîòîðûìè êàæåòñÿ (ñóáúåêòèâíî) ñåãîäíÿ ìàëîðåàëüíîé 4) Takeda èçâåñòíà âûñîêèìè öåíàìè (äàæå íå ñìîòðÿ íà îðèãèíàëüíîñòü ïðåïàðàòîâ) íà ñâîè ïðîäóêòû, îãðàíè÷èâàþùèìè âîçìîæíîñòü øèðîêîãî èõ íàçíà÷åíèÿ |
#3
|
|||
|
|||
Ìåòôîðìèí ôîðåâà?
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
Aims The impact of insulin secretagogues (ISs) on long-term major clinical outcomes in type 2 diabetes remains unclear. We examined mortality and cardiovascular risk associated with all available ISs compared with metformin in a nationwide study. Methods and results All Danish residents >20 years, initiating single-agent ISs or metformin between 1997 and 2006 were followed for up to 9 years (median 3.3 years) by individual-level linkage of nationwide registers. All-cause mortality, cardiovascular mortality, and the composite of myocardial infarction (MI), stroke, and cardiovascular mortality associated with individual ISs were investigated in patients with or without previous MI by multivariable Cox proportional-hazard analyses including propensity analyses. A total of 107 806 subjects were included, of whom 9607 had previous MI. Compared with metformin, glimepiride (hazard ratios and 95% confidence intervals): 1.32 (1.24–1.40), glibenclamide: 1.19 (1.11–1.28), glipizide: 1.27 (1.17–1.38), and tolbutamide: 1.28 (1.17–1.39) were associated with increased all-cause mortality in patients without previous MI. The corresponding results for patients with previous MI were as follows: glimepiride: 1.30 (1.11–1.44), glibenclamide: 1.47 (1.22–1.76), glipizide: 1.53 (1.23–1.89), and tolbutamide: 1.47 (1.17–1.84). Results for gliclazide [1.05 (0.94–1.16) and 0.90 (0.68–1.20)] and repaglinide and [0.97 (0.81–1.15) and 1.29 (0.86–1.94)] were not statistically different from metformin in both patients without and with previous MI, respectively. Results were similar for cardiovascular mortality and for the composite endpoint. Conclusion Monotherapy with the most used ISs, including glimepiride, glibenclamide, glipizide, and tolbutamide, seems to be associated with increased mortality and cardiovascular risk compared with metformin. Gliclazide and repaglinide appear to be associated with a lower risk than other ISs Èñòî÷íèê:[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#4
|
||||
|
||||
Öèòàòà:
 ïðàêòèêå - ÿ íå âèäåë ñèëüíîãî ñàõàðîñíèæàþùåãî ýôôåêòà îò íèõ. |
#5
|
||||
|
||||
Öèòàòà:
À ÷òî êàñàåòñÿ "ìåòôîðìèíà ôîðåâà", òî ìàêðîñîñóäèñòàÿ ïðîòåêöèÿ ìåòôîðìèíà è êàðäèàëüíûå ðèñêè, àññîöèèðîâàííûå ñ ïðè¸ìîì êîìáèíàöèè ñóëüôîíèëìî÷åâèíû, áûëè äîêàçàíû åù¸ â UKPDS è ïîäòâåðæäåíû â ðÿäå êðóïíûõ ïîñëåäóþùèõ èññëåäîâàíèé. Ó ãëèêëàçèäà è ðàíåå èìåëèñü êîçûðè â ðóêàâå ïî êàðäèîïðîòåêöèè, ñàìûìè êðóïíûìè èç êîòîðûõ áûëè ðåçóëüòàòû STENO II è ADVANCE. |
#6
|
|||
|
|||
Íàñ÷åò äîâîëüíî óìåðåííîãî ñàõàðîñíèæàþùåãî ýôôåêòà èíêðåòèíîìèìåòèêîâ è DPP-IV-èíãèáèòîðîâ - ñîãëàñåí; âèäèìî, â áîëüøèíñòâå ñëó÷àåâ ýòè ãðóïïû ïðåïàðàòîâ ïîäõîäÿò äëÿ ÑÄ-2 ñ íåáîëüøèì ñòàæåì.
Ñàìîå ãëàâíîå íà ñåãîäíûøíèé äåíü, íàâåðíîå, âîò ýòî: Öèòàòà:
_____________________________ Âàñèëèé Ñàìèòèí, ýíäîêðèíîëîã |
#7
|
||||
|
||||
Âîò, âñòðåòèëàñü èíòåðåñíàÿ äèñêóññèÿ ýêñïåðòîâ íà Medscape (
(ýòà ñòðàíèöà îáùåäîñòóïíà, íî íóæíî çàðåãèñòðèðîâàòüñÿ). Öèòàòà:
Ïîõîæå, ÷òî â êëèíè÷åñêîé ïðàêòèêå ó ïàöèåíòîâ ñ âïåðâûå âûÿâëåííûì ÑÄ2 ìû âèäèì ñî÷åòàíèå ýôôåêòà ïðåïàðàòà è íàøèõ ðåêîìåíäàöèé ïî äèåòå, ñíèæåíèþ âåñà è ò.ï. Ïðè áëàãîïðèÿòíûõ îáñòîÿòåëüñòâàõ è ñåðüåçíîì îòíîøåíèè ïàöèåíòà ýôôåêò ìîæåò áûòü î÷åíü ñèëüíûé |
#8
|
|||
|
|||
Öèòàòà:
______________________ Âàñèëèé Ñàìèòèí, ýíäîêðèíîëîã |